A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects with Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)
Clinical Trial Grant
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Gilead Sciences, Inc.
Start Date
March 16, 2018
End Date
August 27, 2019
Administered By
Medicine, Rheumatology and Immunology
Awarded By
Gilead Sciences, Inc.
Start Date
March 16, 2018
End Date
August 27, 2019